Duloxetine Capsule, Delayed Release
Product Images NDC 71335-2624

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 71335-2624). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 01)

FDA Label Image

Figure 1 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 02)

This text provides data on the proportion of patients experiencing a relapse over time for both the placebo and duloxetine treatment groups. The graph shows the number of days from randomization to relapse, using the Kaplan-Meier estimator method. *

FDA Label Image

Figure 2 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 03)

This data likely represents the proportion of patients experiencing a relapse over time while being treated with either a placebo or duloxetine. The numbers provided show the time from randomization to relapse in days, with corresponding percentages for each treatment group. The Kaplan-Meier estimator method was likely used to analyze this information for the study.*

FDA Label Image

Figure 1 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 04)

This text seems to provide information about the percentage of patients who showed improvement while taking different doses of Duloxetine (60 mg and 20 mg) and a placebo. It also mentions the percentage improvement in pain from baseline. This information could be part of a clinical study or medical report evaluating the effectiveness of Duloxetine in managing pain.*

FDA Label Image

Figure 2 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 05)

FDA Label Image

Fig 5 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 06)

Percentage of Patients Improved with different dosages of duloxetine and placebo in terms of pain from baseline. The table shows percentage improvement in pain from baseline for Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and Placebo.*

FDA Label Image

Fig 6 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 07)

This text provides information on the percentage of patients improved with different dosages of Duloxetine and a placebo. The percentage of improvement in pain from baseline is shown with varying levels across different treatment groups.*

FDA Label Image

Fig 7 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 08)

This is a description of the percentage of pediatric patients aged 13 to 17 years old with Juvenile Fibromyalgia Syndrome achieving various levels of pain relief at week 12 in Study FM-4. It compares the efficacy of Duloxetine 60mg once daily to placebo in improving pain relief in adolescent patients. The pain relief was measured using the Brief Pain Inventory - Modified Short Form: Adolescent Version Average Pain Score. Duloxetine-treated patients started with 30 mg once daily for 1 week and titrated up to 60 mg once daily over 12 weeks.*

FDA Label Image

Figure 8 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 09)

This text provides information on the percentage of patients improved with a placebo versus Duloxetine 60/120 mg taken once daily. It includes a scale from 0 to 100 for percent improvement in pain from baseline.*

FDA Label Image

Figure 9 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 10)

This text provides information on the percentage of patients improved using placebo and Duloxetine 60 mg. It shows the percentage improvement in pain from baseline using once-daily Duloxetine 60 mg treatment. The data includes a scale from 0 to 100 for pain improvement.*

FDA Label Image

Figure 10 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 11)

This text provides data on the percentage of patients who improved when taking a placebo compared to duloxetine at 60/120 mg dosage once daily. It also includes a graphic showing the percent improvement in pain from the baseline using BOCF methodology.*

FDA Label Image

Image (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 935 1)

FDA Label Image

Image (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 942 1)

FDA Label Image

Label (Lbl713352624)

This is a product label for DULoxetine Delayed-Release Capsules, USP. Each capsule contains 22.4 mg of Duloxetine Hydrochloride equivalent to 20 mg Duloxetine. It is recommended to keep the medication out of reach of children and store it at a temperature between 20°C to 25°C. The usual dosage information can be accessed by scanning the Package Insert QR Code. The product is repackaged by Bryant Ranch Prepack, Inc. and manufactured by Lupin Limited. The NDC number is 71335-2624-1.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.